The DOI matches its Crossref record; 283 of the 283 references it cites were found in a registry or an index.
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Open accessAbstract
CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–283 of 283
Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Zhao, N., Qin, Y., Liu, H., & Cheng, Z. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520617666170419143459 · Cited by 86
Wang, F., Li, L., Liu, B., et al. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.041 · Cited by 86
CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer
Azangou‐Khyavy, M., Ghasemi, M., Khanali, J., Boroomand-Saboor, M., Jamalkhah, M., Soleimani, M., & Kiani, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02062 · Cited by 85
In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9
He, Z., Zhang, Y., Yang, Y., Ma, C., Wang, P., Du, W. T., Li, L., Xiang, R., Song, X., Zhao, X., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.209 · Cited by 84
Nguyen, K. P., Dang, P. N., & Alsberg, E. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.08.012 · Cited by 83
Gao, Q., Ouyang, W., Kang, B., Han, X., Xiong, Y., Ding, R., Li, Y., Wang, F., Huang, L., Chen, L., et al. (2020) · Theranostics · doi:10.7150/thno.42325 · Cited by 79
Ng, S. R., Rideout, W. M., Akama‐Garren, E. H., Bhutkar, A. J., Mercer, K. L., Schenkel, J. M., Bronson, R. T., & Jacks, T. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821893117 · Cited by 78
Intraoperative Assessment and Photothermal Ablation of the Tumor Margins Using Gold Nanoparticles
Wei, Q., Arami, H., Santos, H. A., Zhang, H., Li, Y., He, J., Zhong, D., Ling, D., & Zhou, M. (2021) · Advanced Science · doi:10.1002/advs.202002788 · Cited by 78
Self-citationYe, L., Letchford, K., Heller, M., Liggins, R., Guan, D., Kizhakkedathu, J. N., Brooks, D. E., Jackson, J. K., & Burt, H. M. (2010) · Biomacromolecules · doi:10.1021/bm101080p · Cited by 77
Rapid Microfluidic Preparation of Niosomes for Targeted Drug Delivery
Seleci, D. A., Maurer, V., Stahl, F., Scheper, T. H., & Garnweitner, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194696 · Cited by 77
Yu, Q., Song, H., Xiao, H., Cheng, G., Yu, B., & Xu, F. (2018) · Small · doi:10.1002/smll.201803061 · Cited by 75
Nanotechnology based CRISPR/Cas9 system delivery for genome editing: Progress and prospect
Deng, H., Huang, W., & Zhang, Z. (2019) · Nano Research · doi:10.1007/s12274-019-2465-x · Cited by 75
Nose-to-brain drug delivery mediated by polymeric nanoparticles: influence of PEG surface coating
de Oliveira, E. R., dos Santos, L. C. R., Salomão, M. A., Nascimento, T. L., Oliveira, G. D. A. R., Lião, L. M., & Lima, E. M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00816-2 · Cited by 75
Watanabe, S., Shimada, S., Akiyama, Y., Ishikawa, Y., Ogura, T., Ogawa, K., Ono, H., Mitsunori, Y., Ban, D., Kudo, A., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32072 · Cited by 73
Zhen, S., Liu, Y., Lu, J., Tuo, X., Yang, X., Chen, H., Chen, W., & Li, X. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.312 · Cited by 71
Tumor-targeting peptide functionalized PEG-PLA micelles for efficient drug delivery
Cai, Y., Xu, Z., Shuai, Q., Zhu, F., Xu, J. H., Gao, X., & Sun, X. (2020) · Biomaterials Science · doi:10.1039/c9bm02036e · Cited by 70
Continuous-Flow Production of Liposomes with a Millireactor under Varying Fluidic Conditions
Yanar, F., Mosayyebi, A., Nastruzzi, C., Carugo, D., & Zhang, X. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111001 · Cited by 70
ZIF-C for targeted RNA interference and CRISPR/Cas9 based gene editing in prostate cancer
Poddar, A., Pyreddy, S., Carraro, F., Dhakal, S., Rassell, A., Field, M. R., Reddy, T. S., Falcaro, P., Doherty, C. M., & Shukla, R. (2020) · Chemical Communications · doi:10.1039/d0cc06241c · Cited by 70
Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells
Zheng, X. W., Wan, J., Nur, A. A., Dou, P., Mankin, H. J., Liu, T., & Ouyang, Z. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495714 · Cited by 68
Nanoparticle-based targeted gene therapy for lung cancer.
Lee, H.-Y., Mohammed, K. A., & Nasreen, N. (2016) · PubMed · Cited by 67
Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma
Tang, F., Min, L., Seebacher, N. A., Li, X., Zhou, Y., Hornicek, F. J., Wei, Y., Tu, C., & Duan, Z. (2019) · Journal of Orthopaedic Research® · doi:10.1002/jor.24227 · Cited by 65
Peptide-based targeting of immunosuppressive cells in cancer
Trac, N. T., & Chung, E. J. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.01.006 · Cited by 65
Molecular mechanisms, off‐target activities, and clinical potentials of genome editing systems
Zheng, N., Li, L., & Wang, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.34 · Cited by 65
Perspectives of Dendrimer-based Nanoparticles in Cancer Therapy
Castro, R. I., Forero‐Doria, O., & Guzmán, L. (2018) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201820170387 · Cited by 64
Targeted genomic CRISPR-Cas9 screen identifies MAP4K4 as essential for glioblastoma invasion
Prolo, L. M., Li, A., Owen, S. F., Parker, J. J., Foshay, K. M., Nitta, R. T., Morgens, D. W., Bolin, S., Wilson, C., Leonel, J. C. M. V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50160-w · Cited by 64
Cui, C., Liu, Y., Gerloff, D., Rohde, C., Pauli, C., Köhn, M., Misiak, D., Oellerich, T., Schwartz, S., Schmidt, L., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01570-y · Cited by 63
Zhu, D., Shen, H., Tan, S., Hu, Z., Wang, L., Yu, L., Tian, X., Ding, W., Ren, C., Gao, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.019 · Cited by 62
Zhao, G., Wang, Q., Gu, Q., Qiang, W., Wei, J., Dong, P., Watari, H., Li, W., & Yue, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21863 · Cited by 59
Rehman, M., Ihsan, A., Madni, A., Bajwa, S. Z., Shi, D., Webster, T. J., & Khan, W. S. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s147506 · Cited by 59
Sun, W., He, B., Yang, B., Hu, W., Cheng, S., Xiao, H., Yang, Z., Wen, X., Zhou, L., Xie, H., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0027-6 · Cited by 59
Recent advances in HER2-targeted delivery for cancer therapy
Dhritlahre, R. K., & Saneja, A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.014 · Cited by 58
Janonienė, A., Liu, Z., Baranauskienė, L., Mäkilä, E. M., Ma, M., Salonen, J., Hirvonen, J. J., Zhang, H., Petrikaitė, V., & Santos, H. A. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b04038 · Cited by 56
Self-citationMintz, R. L., Lao, Y., Chi, C., He, S., Li, M., Quek, C. H., Shao, D., Chen, B., Han, J., Wang, S., et al. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10152 · Cited by 53
Liu, C., Xu, X., Zhou, J., Yan, J., Wang, D., & Zhang, H. (2020) · BMC Materials · doi:10.1186/s42833-020-00013-y · Cited by 53
Self-citationMandal, T. N., Karmakar, A., Sharma, S., & Ghosh, S. K. (2017) · The Chemical Record · doi:10.1002/tcr.201700033 · Cited by 50
Adult Stem Cell-Derived Extracellular Vesicles in Cancer Treatment: Opportunities and Challenges
Parfejevs, V., Sagini, K., Buss, A., Soboļevska, K., Llorente, A., Riekstiņa, U., & Ābols, A. (2020) · Cells · doi:10.3390/cells9051171 · Cited by 47
Liu, B., He, X., Zhuo, R., & Cheng, S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.018 · Cited by 46
Zhou, X., Li, R., Jing, R., Zuo, B., & Zheng, Q. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03207-9 · Cited by 45
He, C., Ali, D. J., Xu, H., Kumaravel, S., Si, K., Li, Y., Sun, B., Ma, J., & Xiao, Z. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112040 · Cited by 45
Krämer, M., Kopaczyñska, M., Krause, S., et al. (2007) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.21996 · Cited by 44
Peptides as Potential Anticancer Agents
Aaghaz, S., Gohel, V., & Kamal, Ä. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190125161517 · Cited by 43
Roidos, P., Sungalee, S., Benfatto, S., Serçin, Ö., Stütz, A. M., Abdollahi, A., Mauer, J., Zenke, F. T., Korbel, J. O., & Mardin, B. R. (2020) · Nature Communications · doi:10.1038/s41467-020-17962-3 · Cited by 43
Yin, H., Yuan, X., Luo, L., Lu, Y., Qin, B., Zhang, J., Shi, Y., Zhu, C., Yang, J., Li, X., et al. (2020) · Advanced Science · doi:10.1002/advs.201903381 · Cited by 42
Li, H., Zhao, L., Lau, Y. S., Zhang, C., & Han, R. (2020) · Oncogene · doi:10.1038/s41388-020-01523-5 · Cited by 41
Zhao, Q., Qian, Q., Cao, D., Yang, J., Gui, T., & Shen, K. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0406-z · Cited by 40
Zhang, Q., Kuang, G., He, S., Liu, S., Lu, H., Li, X., Zhou, D., & Huang, Y. (2020) · Nano Research · doi:10.1007/s12274-020-3066-4 · Cited by 40
Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
Wu, X., Ma, W., Mei, C., Chen, X., Yao, Y., Liu, Y., Qin, X., & Yuan, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01603-0 · Cited by 38
Yan, F., Ying, L., Li, X., Qiao, B., Meng, Q., Yu, L., Yuan, X., Ren, S.-T., Chan, D. W., Shi, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16638 · Cited by 37
Simbulan-Rosenthal, C. M., Dougherty, R., Vakili, S., Ferraro, A., Kuo, L., Alobaidi, R., Aljehane, L., Gaur, A., Sykora, P., Glasgow, E. F., et al. (2019) · Cancers · doi:10.3390/cancers11101490 · Cited by 36
Ninjurin2 overexpression promotes glioma cell growth
Zhou, L.-N., Li, P., Cai, S., Li, G., & Liu, F. (2019) · Aging · doi:10.18632/aging.102515 · Cited by 36
Peng, H., Le, C., Wu, J., Li, X., Zhang, H., & Le, X. C. (2020) · ACS Nano · doi:10.1021/acsnano.9b05276 · Cited by 36
Self-citationSengupta, S., Krishnan, M. A., Chattopadhyay, S., & Chelvam, V. (2019) · Cancer Reports · doi:10.1002/cnr2.1169 · Cited by 34
Ouyang, Q., Liu, Y., Tan, J., Li, J., Yang, D., Zeng, F., Huang, W., Kong, Y., Liu, Z., Zhou, H., et al. (2019) · PubMed · Cited by 34
Ercolano, G., Cicco, P. D., Rubino, V., Terrazzano, G., Ruggiero, G., Carriero, R., Kunderfranco, P., & Ianaro, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01456 · Cited by 34
Peng, C., Yu, M., Hsieh, J., Kapur, P., & Zheng, J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201905738 · Cited by 33
He, X., Liu, B., Peng, Y., Zhuo, R., & Cheng, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b17481 · Cited by 31
Advancements in CRISPR/Cas9 technology—Focusing on cancer therapeutics and beyond
Mirza, Z., & Karim, S. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.026 · Cited by 31
CRISPR deletion of MIEN1 in breast cancer cells
Treuren, T. V., & Vishwanatha, J. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204976 · Cited by 30
Nanotechnology in the arena of cancer immunotherapy
Asadujjaman, M., Cho, K. H., Jang, D.-J., Kim, J.-E., & Jee, J. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01207-4 · Cited by 29
Gonzalez-Salinas, F., Rojo, R., Martínez-Amador, C., Herrera-Gamboa, J. G., & Treviño, V. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.172 · Cited by 29
Mengoni, M., Braun, A. D., Gaffal, E., & Tüting, T. (2020) · International Journal of Cancer · doi:10.1002/ijc.33252 · Cited by 29
Singh, S. K., Gordetsky, J., Bae, S., Acosta, E. P., Lillard, J. W., & Singh, R. (2020) · Cells · doi:10.3390/cells9091976 · Cited by 29
Hussmann, D., Madsen, A. T., Jakobsen, K. R., Luo, Y., Sørensen, B. S., & Nielsen, A. L. (2017) · Oncotarget · doi:10.18632/oncotarget.16350 · Cited by 28
Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells
Bakke, J., Wright, W. C., Zamora, A. E., Oladimeji, P. O., Crawford, J. C., Brewer, C., Autry, R. J., Evans, W. E., Thomas, P. G., & Chen, T. (2019) · BMC Cancer · doi:10.1186/s12885-019-5455-1 · Cited by 28
Nagler, A., Vredevoogd, D. W., Alon, M., Cheng, P. F., Trabish, S., Kalaora, S., Arafeh, R., Goldin, V., Levesque, M. P., Peeper, D. S., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12825 · Cited by 28
Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing
Xu, Y., Liu, R., & Dai, Z. (2020) · Nanoscale · doi:10.1039/d0nr05452f · Cited by 28
Kim, H., Lee, S., Lim, J., Yoo, J., & Hwang, D. (2020) · Cell Proliferation · doi:10.1111/cpr.12965 · Cited by 28
Fabrication of dendrimer-releasing lipidic nanoassembly for cancer drug delivery
Sun, Q., Ma, X., Zhang, B., Zhou, Z., Jin, E., Shen, Y., Kirk, E. A. V., Murdoch, W. J., Radosz, M., & Sun, W. (2016) · Biomaterials Science · doi:10.1039/c6bm00189k · Cited by 25
Wu, B., Zhang, L.-J., Zhang, C., Deng, K., Ao, Y.-W., Mei, H., Zhou, W., Wang, C., Yu, H., & Huang, S. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00516 · Cited by 24
Carlisle, S. M., Trainor, P. J., Hong, K. U., Doll, M. A., & Hein, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-66863-4 · Cited by 24
CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle
Slotta, C., Schlüter, T., Ruiz-Perera, L. M., Kadhim, H. M., Tertel, T., Henkel, E., Hübner, W., Greiner, J. F. W., Huser, T. R., Kaltschmidt, B., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182373 · Cited by 23
Post, J. B., Hami, N., Mertens, A. E. E., Elfrink, S., Bos, J. L., & Snippert, H. J. G. (2019) · Oncotarget · doi:10.18632/oncotarget.26677 · Cited by 23
Yang, X., Chen, Q., Yang, J., Wu, S., Liu, J., Li, Z., Liu, D., Chen, X., & Qiu, Y. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b16764 · Cited by 22
pRB2/p130 target genes in non-small lung cancer cells identified by microarray analysis
Russo, G., Claudio, P. P., Fu, Y., Stiegler, P., Yu, Z., Macaluso, M., & Giordano, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206866 · Cited by 21
Blossom of CRISPR technologies and applications in disease treatment
Liu, H., Wang, L., & Luo, Y. (2018) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2018.10.003 · Cited by 21
Knockdown of Trio by CRISPR/Cas9 suppresses migration and invasion of cervical cancer cells
Hou, C., Zhuang, Z., Deng, X., Xu, Y., Zhang, P., & Zhu, L. (2017) · Oncology Reports · doi:10.3892/or.2017.6117 · Cited by 19
Lyu, Y., He, S., Li, J., Jiang, Y., Sun, H., Miao, Y., & Pu, K. (2019) · Angewandte Chemie · doi:10.1002/ange.201909264 · Cited by 19
Chen, W., Ding, R., Tang, J., Li, H., Chen, C., Zhang, Y., Zhang, Q., & Zhu, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s236374 · Cited by 17
Grant, C. V., Cai, S., Risinger, A. L., Liang, H., O’Keefe, B. R., Doench, J. G., Cichewicz, R. H., & Mooberry, S. L. (2020) · Journal of Natural Products · doi:10.1021/acs.jnatprod.0c00642 · Cited by 15
Garcia‐Peterson, L. M., Ndiaye, M. A., Chhabra, G., Singh, C. K., Guzmán‐Pérez, G., Iczkowski, K. A., & Ahmad, N. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13305 · Cited by 14
PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells
Witte, K. E., Slotta, C., Lütkemeyer, M., Kitke, A., Coras, R., Simon, M., Kaltschmidt, C., & Kaltschmidt, B. (2020) · Scientific Reports · doi:10.1038/s41598-020-77958-3 · Cited by 14
Aleksandrowicz, R., Taciak, B., & Król, M. (2017) · PubMed · Cited by 10
Kim, H., Jeong, H., Cho, Y., Lee, J., Nam, K. T., & Lee, H. (2018) · Laboratory Animal Research · doi:10.5625/lar.2018.34.4.257 · Cited by 9
Cited by
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
Nanoparticles in Clinical Translation for Cancer Therapy
Mundekkad, D., & Cho, W. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031685 · Cited by 305
The application of the CRISPR-Cas system in antibiotic resistance
Tao, S., Chen, H., Li, N., & Liang, W. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s370869 · Cited by 147
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Metadata
- Authors
- Xu, X., Liu, C., Wang, Y., Koivisto, O., Zhou, J., Shu, Y., & Zhang, H.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 176
- Pages
- 113891
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W3185214580
- Cited by
- 289
- References
- 283
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.